Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kuanxiong Qiwu Ji is a Traditional Chinese Medicine (TCM) aerosol formulation primarily used for the treatment of coronary heart disease and angina pectoris. It is composed of volatile oils and extracts from *Asarum sieboldii*, *Santalum album*, *Alpinia officinarum*, *Piper longum*, and *Borneolum syntheticum*. The drug is administered sublingually to achieve rapid absorption, bypassing first-pass metabolism to provide quick relief of chest pain. Its mechanism involves promoting vasodilation of coronary arteries, reducing myocardial oxygen consumption, and exerting anti-inflammatory and anti-platelet effects. In clinical research, it is being evaluated for its potential to improve left ventricular remodeling and cardiopulmonary function in patients following emergency percutaneous coronary intervention (PCI) for acute myocardial infarction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on kuanxiong qiwu ji.